VEGF165b Antibody (Mouse mAb) [B10E21]

Catalog No.: F5992

    Application: Reactivity:
    • Immunohistochemical analysis of formalin fixed paraffin embedded human placenta tissue with F5992 at 1:50 dilution.
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    推奨WB希釈率: 1:50

    使用情報

    Dilution
    1:1000
    1:50
    1:60
    1:50
    1:50
    1:50
    Application
    WB, IHC, IF
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    44 kDa 23 kDa, 46 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human Placenta
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:50), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    VEGF165b Antibody (Mouse mAb) [B10E21] detects endogenous levels of total VEGF165b protein.
    タンパク質の局在
    細胞質、小胞体、細胞外マトリックス、ゴルジ装置、細胞核、細胞外環境
    Uniprot ID
    P15692
    Clone
    B10E21
    Synonym(s)
    MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF
    Background
    VEGF165b arises from alternative splicing of exon 8 in the vascular endothelial growth factor A (VEGF-A) gene, differing from the proangiogenic VEGF165a isoform by six amino acids at the C-terminus—VEGF165a terminating with the sequence CDKPRR, while VEGF165b possesses the terminal sequence SLTRKD derived from the distal splice acceptor site in exon 8b. This structural divergence alters receptor binding properties and downstream signaling consequences without changing the overall topology of receptor engagement, positioning VEGF165b as an endogenous regulator that modulates rather than completely blocks VEGF-mediated angiogenesis. VEGF165b functions as an antagonist of proangiogenic VEGF165a by preferentially binding to VEGF receptor 1 (VEGFR1) over VEGFR2, preventing VEGF165a from activating the VEGFR1-STAT3 signaling axis that drives angiogenesis and perfusion recovery in peripheral arterial disease (PAD) and other ischemic conditions. The protein exhibits elevated expression in human PAD muscle biopsies compared to control tissues, with higher binding affinity to VEGFR1 relative to VEGF165a, and VEGF165b levels correlate inversely with VEGFR1 activation status but not VEGFR2 activation, challenging the traditional view that VEGF165b primarily antagonizes VEGFR2 signaling. Inhibition of VEGF165b through isoform-specific monoclonal antibodies enhances perfusion recovery in severe PAD without activating VEGFR2 signaling, instead increasing VEGFR1 activation and promoting VEGFR1-STAT3 binding interactions that trigger STAT3 phosphorylation and nuclear translocation independent of Janus-activated kinase 1/2 (JAK1/JAK2) activation. The protein binds VEGFR2 with similar affinity to VEGF165a but fails to induce receptor phosphorylation and downstream mitogen-activated protein kinase (MAPK) and phospholipase C gamma (PLCγ) activation, instead competitively inhibiting VEGF165a-mediated VEGFR2 autophosphorylation at tyrosine residues Y1175 and Y1214, which are essential for endothelial cell proliferation and migration. VEGF165b inhibits VEGF165a-stimulated endothelial cell proliferation, migration, and capillary tube formation with an IC50 approximately tenfold lower than the concentration of VEGF165a present, demonstrating potent inhibitory capacity even when expressed at substoichiometric levels relative to proangiogenic isoforms. The splice variant exhibits downregulation in multiple human malignancies, including renal cell carcinoma, prostate cancer, and melanoma, with loss of VEGF165b expression correlating with increased tumor angiogenesis, progression, and metastatic potential, while exogenous VEGF165b administration inhibits tumor growth and vascular density. VEGF165b expression becomes regulated at the level of alternative splicing through factors including transforming growth factor-beta 1 (TGF-β1) and insulin-like growth factor 1 (IGF-1), which promote proximal splice site selection favoring VEGF165a production, whereas serine-arginine-rich splicing factor 1 (SRSF1) promotes distal splice site usage, generating VEGF165b, positioning splicing factor availability and activity as determinants of the VEGF165a/VEGF165b expression ratio. The protein regulates immune cell function beyond endothelial effects, augmenting natural killer cell cytolytic activity against leukemia cells through upregulation of perforin and granzyme B expression via VEGFR1-phospholipase C (PLC) pathway activation, demonstrating immunomodulatory capabilities distinct from simple anti-angiogenic mechanisms. VEGF165b exhibits tissue-specific expression patterns with high levels detected in healthy kidney glomeruli and retinal pigment epithelium, maintaining basal vascular quiescence and preventing pathological neovascularization, while reduced expression in diabetic retinopathy and age-related macular degeneration associates with aberrant angiogenesis.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください